<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03945812</url>
  </required_header>
  <id_info>
    <org_study_id>INDV-0909012</org_study_id>
    <nct_id>NCT03945812</nct_id>
  </id_info>
  <brief_title>Granulocyte Colony Stimulating Factor Versus Platelet Rich Plasma and Outcomes of Frozen Embryo Transfer</brief_title>
  <official_title>The Impact of Using Granulocyte Colony Stimulating Factor (G-CSF) Versus Platelet Rich Plasma (PRP) on the Outcomes of Frozen Embryo Transfer; Double-blinded Randomized Placebo-controlled Trial (Endotrial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ClinAmygate</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wael Elbanna Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Research Center, Egypt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ClinAmygate</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rationale behind this current study is to assess the impact of using PRP versus GCSF on
      the outcomes of frozen embryo transfer in term of clinical pregnancy rates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      INTRODUCTION AND STUDY RATIONALE Despite the advancements in the treatment of infertility,
      repeated failure of implantation continues as a challenging difficulty.

      Embryo implantation is affected by many factors. Many efforts were made to improve the
      implantation rate by different methods blastocyst transfer, assisted hatching,
      preimplantation genetic screening, hysteroscopy, removal of hydrosalpinges and endometrial
      scratch. Furthermore, infertility specialists suggested some empirical methods like the
      infusion in the uterine cavity of platelet-rich plasma (PRP) in patients with thin
      endometrium which has been shown to be effective in improving the pregnancy rate.

      Another factor is granulocyte colony stimulating factor (G-CSF) which has receptors in
      endometrial cells and may have a role in implantation. The use of G-CSF in assisted
      reproductive technology (ART) has been tried by many research studies either via intrauterine
      or systemic administration.

      There is only one study compared the impact of PRP and GCSF administration on the pregnancy
      rate and on the endometrial thickness with a small sample size.

      The rationale behind this current study is to assess the impact of using PRP versus GCSF on
      the outcomes of frozen embryo transfer in term of clinical pregnancy rates.

      STUDY OBJECTIVES

      Primary:

      The primary objective of the study is to compare the clinical pregnancy rate determined by
      presence of fetal heart beat in transvaginal ultrasound after embryo transfer in all groups.

      Secondary:

      To compare the following in the three study arms:

        -  Chemical pregnancy determined by positive serum β-HCG, 2 weeks after embryo transfer.

        -  Clinical pregnancy rate adjusted by the endometrial thickness (thin versus normal) in
           all groups.

        -  The midluteal endometrial thickness in all groups (histopathology &amp; TVUS).

        -  The number of women who had thin endometrium and reaches endometrial thickness ≥ 7 mm
           after using G-CSF or PRP.

        -  Implantation rate

        -  Miscarriage rate

        -  Live-birth rate
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2019</start_date>
  <completion_date type="Anticipated">June 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The clinical pregnancy rate</measure>
    <time_frame>Up to 2 weeks</time_frame>
    <description>The clinical pregnancy rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chemical pregnancy rate</measure>
    <time_frame>Up to 2 weeks</time_frame>
    <description>Chemical pregnancy rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endometrial thickness</measure>
    <time_frame>Up to 2 weeks</time_frame>
    <description>endometrial thickness in all groups (histopathology &amp; TVUS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>Up to 2 weeks</time_frame>
    <description>Implantation rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miscarriage rate</measure>
    <time_frame>With second trimester</time_frame>
    <description>Miscarriage rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live-birth rate</measure>
    <time_frame>1 year</time_frame>
    <description>Live-birth rate</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">390</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Granulocyte Colony Stimulating Factor Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women in this group will receive G-CSF with conventional hormonal therapy:
Estradiol valerate 6mg/day from day 2 of menstrual cycle Vaginal sildenafil citrate 25mg / 6 hours Then frozen embryo transfer cycle will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Platelet Rich Plasma Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women in this group will receive PRP with conventional hormonal therapy:
Estradiol valerate 6mg/day from day 2 of menstrual cycle Vaginal sildenafil citrate 25mg / 6 hours Then frozen embryo transfer cycle will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Women in this group will receive saline with conventional hormonal therapy:
Estradiol valerate 6mg/day from day 2 of menstrual cycle Vaginal sildenafil citrate 25mg / 6 hours Then frozen embryo transfer cycle will be performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granulocyte Colony Stimulating Factor</intervention_name>
    <description>Filgrastim, Amgen, California, USA 300 mg/1.0 mL</description>
    <arm_group_label>Granulocyte Colony Stimulating Factor Arm</arm_group_label>
    <other_name>Filgrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Platelet Rich Plasma Arm</intervention_name>
    <description>Platelet Rich Plasma Arm</description>
    <arm_group_label>Platelet Rich Plasma Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline 9%</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Saline 9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All women aged 20-40 years

          -  non-smoker

          -  BMI &lt; 30

          -  Normal endometrial cavity confirmed by hysteroscopy

        Exclusion Criteria:

          -  History of anti-phospholipid syndrome confirmed by serological tests.

          -  History of any hematological and immunological disorders

          -  History of chromosomal or genetic abnormalities in the patient or in the family

          -  Any uterine abnormalities (congenital or acquired)

          -  Previous uterine surgeries except caesarean section

          -  Hypersensitivity to G-CSF

          -  Uncontrolled systemic disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emad RH Issak, Dip</last_name>
    <role>Study Director</role>
    <affiliation>ClinAmygate</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emad RH Issak, Dip</last_name>
    <phone>00201272228989</phone>
    <email>dr.emad.r.h.issak@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wael SS Elbanna, MD</last_name>
    <phone>00201227760402</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wael El-Banna Clinic</name>
      <address>
        <city>Maadi</city>
        <state>Cairo</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wael SS El-Banna, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Mehrafza M, Kabodmehri R, Nikpouri Z, Pourseify G, Raoufi A, Eftekhari A, Samadnia S, Hosseini A. Comparing the Impact of Autologous Platelet-rich Plasma and Granulocyte Colony Stimulating Factor on Pregnancy Outcome in Patients with Repeated Implantation Failure. J Reprod Infertil. 2019 Jan-Mar;20(1):35-41.</citation>
    <PMID>30859080</PMID>
  </reference>
  <reference>
    <citation>Coughlan C, Ledger W, Wang Q, Liu F, Demirol A, Gurgan T, Cutting R, Ong K, Sallam H, Li TC. Recurrent implantation failure: definition and management. Reprod Biomed Online. 2014 Jan;28(1):14-38. doi: 10.1016/j.rbmo.2013.08.011. Epub 2013 Sep 14. Review.</citation>
    <PMID>24269084</PMID>
  </reference>
  <reference>
    <citation>Rinehart J. Recurrent implantation failure: definition. J Assist Reprod Genet. 2007 Jul;24(7):284-7. Epub 2007 Aug 3. Review.</citation>
    <PMID>17674185</PMID>
  </reference>
  <reference>
    <citation>Chang Y, Li J, Chen Y, Wei L, Yang X, Shi Y, Liang X. Autologous platelet-rich plasma promotes endometrial growth and improves pregnancy outcome during in vitro fertilization. Int J Clin Exp Med. 2015 Jan 15;8(1):1286-90. eCollection 2015.</citation>
    <PMID>25785127</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 8, 2019</study_first_submitted>
  <study_first_submitted_qc>May 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2019</study_first_posted>
  <last_update_submitted>July 19, 2020</last_update_submitted>
  <last_update_submitted_qc>July 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>ClinAmygate</investigator_affiliation>
    <investigator_full_name>Emad Roushdy</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>GCSF</keyword>
  <keyword>PRP</keyword>
  <keyword>Pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

